Long-term safety of zonisamide (25 mg/day) in DLB patients: Post-hoc analysis of phase 3 trial (1)

Kentaro Takai

Presentation information

Japanese Poster Session

[Pj-043] Parkinsonism and Related disorders (zonisamide and rotigotine)

Thu. May 23, 2019 5:50 PM - 7:05 PM Poster Exhibition (Osaka International Convention Center 3F Event Hall)

Chair:Yasushi Shimo(Department of Neurology, Juntendo University School of Medicine)

[Pj-043-2] Long-term safety of zonisamide (25 mg/day) in DLB patients: Post-hoc analysis of phase 3 trial (1)

Kentaro Takai¹, Kazuko Hasegawa², Toshinari Odawara³, Kenji Kochi⁴, Masaaki Tagawa¹, Miho Murata⁵, Kenji Kosaka⁶ (1.Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., 2.Neurology, Sagamihara National Hospital, 3.Health Management Center, Yokohama City University, 4.Data Science, Sumitomo Dainippon Pharma Co., Ltd., 5.Neurology, National Center of Neurology and Psychiatry, 6.Shonan Inaho Clinic)

Abstract password authentication.
Password is written on a pocket program and name badge.